JP6616315B2 - シース取外し機構 - Google Patents
シース取外し機構 Download PDFInfo
- Publication number
- JP6616315B2 JP6616315B2 JP2016558392A JP2016558392A JP6616315B2 JP 6616315 B2 JP6616315 B2 JP 6616315B2 JP 2016558392 A JP2016558392 A JP 2016558392A JP 2016558392 A JP2016558392 A JP 2016558392A JP 6616315 B2 JP6616315 B2 JP 6616315B2
- Authority
- JP
- Japan
- Prior art keywords
- sheath
- cap
- sheath removal
- protective needle
- needle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000007246 mechanism Effects 0.000 title claims description 53
- 230000001681 protective effect Effects 0.000 claims description 139
- 238000012377 drug delivery Methods 0.000 claims description 89
- 239000003814 drug Substances 0.000 claims description 79
- 229940079593 drug Drugs 0.000 claims description 78
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 83
- 108010011459 Exenatide Proteins 0.000 description 49
- 229960001519 exenatide Drugs 0.000 description 49
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 239000004033 plastic Substances 0.000 description 15
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000000576 coating method Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- -1 carboxymethyl hepta decanoyl Chemical group 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 108010015174 exendin 3 Proteins 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
- A61M5/3204—Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3213—Caps placed axially onto the needle, e.g. equipped with finger protection guards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3216—Caps placed transversally onto the needle, e.g. pivotally attached to the needle base
- A61M5/3219—Semi-automatic repositioning of the cap, i.e. in which the repositioning of the cap to the needle covering position requires a deliberate action by the user to trigger the repositioning of the cap, e.g. manual release of spring-biased cap repositioning means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3257—Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
Description
遠位面と、
遠位面から近位方向に延び、保護用ニードルシースを受けるための空間を画成する少なくとも1つの可撓性シース取外しビームであって、保護用ニードルシースと係合するように適用された少なくとも1つのレッジを含む、少なくとも1つの可撓性シース取外しビームとを含み、ここで、少なくとも1つの可撓性シース取外しビームは、保護用ニードルシースと係合するには、遠位面にほぼ垂直となる第1の位置に配設され、保護用ニードルシースを受けるには、遠位面にほぼ垂直とならない(non−approximately perpendicular angle)第2の位置に配設される。
ム11.3が保護用ニードルシース5から係合解除されるのを防止することができる。
ここで、一実施形態において、薬学的に活性な化合物は、最大1500Daまでの分子量を有し、および/または、ペプチド、タンパク質、多糖類、ワクチン、DNA、RNA、酵素、抗体もしくはそのフラグメント、ホルモンもしくはオリゴヌクレオチド、または上述の薬学的に活性な化合物の混合物であり、
ここで、さらなる実施形態において、薬学的に活性な化合物は、糖尿病、または糖尿病性網膜症などの糖尿病関連の合併症、深部静脈血栓塞栓症または肺血栓塞栓症などの血栓塞栓症、急性冠症候群(ACS)、狭心症、心筋梗塞、がん、黄斑変性症、炎症、枯草熱、アテローム性動脈硬化症および/または関節リウマチの処置および/または予防に有用であり、
ここで、さらなる実施形態において、薬学的に活性な化合物は、糖尿病または糖尿病性網膜症などの糖尿病に関連する合併症の処置および/または予防のための少なくとも1つのペプチドを含み、
ここで、さらなる実施形態において、薬学的に活性な化合物は、少なくとも1つのヒトインスリンもしくはヒトインスリン類似体もしくは誘導体、グルカゴン様ペプチド(GLP−1)もしくはその類似体もしくは誘導体、またはエキセンジン−3もしくはエキセンジン−4もしくはエキセンジン−3もしくはエキセンジン−4の類似体もしくは誘導体を含む。
H−(Lys)4−desPro36,desPro37エキセンジン−4(1−39)−NH2、
H−(Lys)5−desPro36,desPro37エキセンジン−4(1−39)−NH2、
desPro36エキセンジン−4(1−39)、
desPro36[Asp28]エキセンジン−4(1−39)、
desPro36[IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,IsoAsp28]エキセンジン−(1−39)、
desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14Trp(O2)25,IsoAsp28]エキセンジン−4(1−39);または
desPro36[Asp28]エキセンジン−4(1−39)、
desPro36[IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,IsoAsp28]エキセンジン−(1−39)、
desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
(ここで、基−Lys6−NH2が、エキセンジン−4誘導体のC−末端に結合していてもよい);
desPro36エキセンジン−4(1−39)−Lys6−NH2(AVE0010)、
H−(Lys)6−desPro36[Asp28]エキセンジン−4(1−39)−Lys6−NH2、
desAsp28Pro36,Pro37,Pro38エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro38[Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
H−desAsp28Pro36,Pro37,Pro38[Trp(O2)25]エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
desMet(O)14,Asp28Pro36,Pro37,Pro38エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2;
desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Lys6−desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
H−desAsp28,Pro36,Pro37,Pro38[Met(O)14,Trp(O2)25]エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(S1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2;
または前述のいずれか1つのエキセンジン−4誘導体の薬学的に許容される塩もしくは溶媒和化合物
から選択される。
Claims (15)
- 薬剤送達デバイス(1)内に配置可能な薬剤容器(3)から保護用ニードルシース(5)を取り外すためのシース取外し機構(15)であって、
薬剤送達デバイス(1)の遠位端に取付け可能なキャップ(11)を含み、
ここで、該キャップ(11)は、保護用ニードルシース(5)と係合するように適用された少なくとも1つのレッジ(11.6)を含み、
ここで、シース取外し機構(15)は、薬剤送達デバイス(1)のケース(2)に配置された内側ケースワーク(2.2)とニードルシュラウド(7)の一部分(7.4)をさらに含み、
ここで、一部分(7.4)またはケースワーク(2.2)は、薬剤容器(3)を保護用ニードルシース(5)とともにケース(2)に挿入している間、シース取外しビーム(11.3)が半径方向外方に偏向するのを可能とするように適用される、前記シース取外し機構。 - レッジ(11.6)は、キャップ(11)に配置された少なくとも1つのシース取外しビーム(11.3)にそれぞれ配置される、請求項1に記載のシース取外し機構(15)。
- シース取外しビーム(11.3)は、キャップ(11)の遠位面(11.10)から近位方向(P)に延び、またはキャップ(11)の遠位面から近位方向(P)に延びる内側スリーブの一部である、請求項2に記載のシース取外し機構(15)。
- シース取外しビーム(11.3)は、可撓性である、請求項2または3に記載のシース取外し機構(15)。
- レッジ(11.6)は、可撓性である、請求項1〜4のいずれか1項に記載のシース取外し機構(15)。
- 内側ケースワーク(2.2)は、キャップ(11)をケース(2)から離して動かす間
、シース取外しビーム(11.3)を半径方向外方に支持しその半径方向外方の偏向を防止するように適用される、請求項2〜5のいずれか1項に記載のシース取外し機構(15)。 - 一部分(7.4)は、キャップ(11)をケース(2)から離して動かす間、シース取外しビーム(11.3)を半径方向外方に支持しその半径方向外方の偏向を防止するように適用される、請求項2〜5のいずれか1項に記載のシース取外し機構(15)。
- レッジ(11.6)は、保護用ニードルシース(5)の近位端(5.1)の近位方向後方に、または保護用ニードルシース(5)内の側方凹部に係合するように適用される、請求項1〜7のいずれか1項に記載のシース取外し機構(15)。
- 保護用ニードルシース(5)を挿入している間、シース取外しビーム(11.3)を半径方向外方に偏向させるように、保護用ニードルシース(5)と係合するための傾斜部(11.4)をシース取外しビーム(11.3)にさらに含む、請求項2〜8のいずれか1項に記載のシース取外し機構(15)。
- シース取外しビーム(11.3)、および/または一部分(7.4)の近位面(7.2)、またはケースワーク(2.2)は、キャップ(11)をケース(2)から取り外す間、シース取外しビーム(11.3)を半径方向内方に偏向させるように傾斜している、請求項6〜9のいずれか1項に記載のシース取外し機構(15)。
- レッジ(11.6)は、可撓性シース取外しビーム(11.3)が弛緩状態にあるとき、レッジ間に、保護用ニードルシース(5)を通すことが可能となるほど十分に広い間隙をもたらし、ここで、1つ以上のスナップ嵌合部(11.7)は、シース取外しビーム(11.3)が半径方向内方に偏向すると、隣接する可撓性シース取外しビーム(11.3)と係合するように、可撓性シース取外しビーム(11.3)に配置される、請求項2〜10のいずれか1項に記載のシース取外し機構(15)。
- ニードルシュラウド(7)は、近位方向(P)に動かすと、可撓性シース取外しビーム(11.3)を半径方向内方に偏向させるように適用される、請求項11に記載のシース取外し機構(15)。
- 1つまたはそれ以上の孔(11.8)または側方アパーチャ(11.9)または開口部(11.11)は、少なくとも1つの組付け具を挿入することが可能となるように、キャップ(11)の遠位面(11.10)または側方領域に配置されている、請求項1〜12のいずれか1項に記載のシース取外し機構(15)。
- 側方アパーチャ(11.9)、または開口部(11.11)から挿入され、2つのシース取外しビーム(11.3)の間でそれらを広げ離すように係合し、それによってシース取外しビームを半径方向外方に偏向させ、内方レッジ(11.6)によって画成された間隙を、保護用ニードルシース(5)を通すことが可能となる程度まで広げるように適用された、楔形組付け具(16)を含む、請求項13に記載のシース取外し機構(15)。
- 薬剤送達デバイス(1)内に配置可能な薬剤容器(3)から保護用ニードルシース(5)を取り外すためのシース取外し機構(15)であって、
薬剤送達デバイス(1)の遠位端に取付け可能なキャップ(11)を含み、
ここで、該キャップ(11)は、保護用ニードルシース(5)と係合するように適用された少なくとも1つのレッジ(11.6)を含み、
レッジ(11.6)は、可撓性シース取外しビーム(11.3)が弛緩状態にあるとき
、レッジ間に、保護用ニードルシース(5)を通すことが可能となるほど十分に広い間隙をもたらし、ここで、1つ以上のスナップ嵌合部(11.7)は、シース取外しビーム(11.3)が半径方向内方に偏向すると、隣接する可撓性シース取外しビーム(11.3)と係合するように、可撓性シース取外しビーム(11.3)に配置される、前記シース取外し機構。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14162455.1 | 2014-03-28 | ||
EP14162455.1A EP2923716A1 (en) | 2014-03-28 | 2014-03-28 | Cap having a sheath removal mechanism |
PCT/EP2015/056687 WO2015144871A1 (en) | 2014-03-28 | 2015-03-27 | Sheath removal mechanism |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017508548A JP2017508548A (ja) | 2017-03-30 |
JP2017508548A5 JP2017508548A5 (ja) | 2018-04-26 |
JP6616315B2 true JP6616315B2 (ja) | 2019-12-04 |
Family
ID=50389934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016558392A Active JP6616315B2 (ja) | 2014-03-28 | 2015-03-27 | シース取外し機構 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10188802B2 (ja) |
EP (3) | EP2923716A1 (ja) |
JP (1) | JP6616315B2 (ja) |
CN (1) | CN106132462B (ja) |
DK (1) | DK3122403T3 (ja) |
TW (1) | TW201603853A (ja) |
WO (1) | WO2015144871A1 (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2923716A1 (en) * | 2014-03-28 | 2015-09-30 | Sanofi-Aventis Deutschland GmbH | Cap having a sheath removal mechanism |
CN107683158B (zh) | 2015-06-04 | 2021-05-14 | 麦迪麦珀医疗工程有限公司 | 用于药物释放装置的筒插入 |
GB2541445B (en) * | 2015-08-20 | 2018-04-18 | Owen Mumford Ltd | Injection device |
WO2017098438A1 (en) | 2015-12-08 | 2017-06-15 | Becton Dickinson France S.A.S. | Cap for medical injector |
US10737036B2 (en) | 2015-12-08 | 2020-08-11 | Becton Dickinson France S.A.S. | Housing and cap for medical injector |
KR102209807B1 (ko) * | 2015-12-08 | 2021-01-29 | 벡톤 디킨슨 프랑스 | 의료용 주입기용 반구형 부분을 구비한 캡 |
CN108290012B (zh) * | 2015-12-08 | 2022-04-08 | 贝克顿迪金森法国公司 | 用于医疗注射器的t形帽 |
WO2017198589A1 (en) | 2016-05-18 | 2017-11-23 | Sanofi-Aventis Deutschland Gmbh | Sheath remover and methods for assembly thereof |
US10363378B2 (en) | 2016-06-15 | 2019-07-30 | Shl Medical Ag | Cap assembly for medicament delivery device |
JP6895462B2 (ja) | 2016-06-22 | 2021-06-30 | アンタレス・ファーマ・インコーポレーテッド | 針遮蔽体取り外し器 |
US10583255B2 (en) * | 2016-07-27 | 2020-03-10 | Shl Medical Ag | Medicament container assembly for a medicament delivery device |
US10300214B2 (en) * | 2016-07-27 | 2019-05-28 | Shl Medical Ag | Cap assembly for a medicament delivery device |
EP3490647B1 (de) | 2016-07-28 | 2021-10-06 | Ypsomed AG | Injektionsvorrichtung mit äusserer kappe mit nadelschutzkappenentfernerelement und verfahren zum montieren einer injektionsvorrichtung |
CH712753A2 (de) * | 2016-07-28 | 2018-01-31 | Tecpharma Licensing Ag | Trennen einer Nadelschutzkappe von einem Produktbehälter und Verfahren zum Montieren einer Injektionsvorrichtung. |
US11141542B2 (en) | 2016-10-13 | 2021-10-12 | Shl Medical Ag | Sub-assembly, a medicament delivery device and a method of assembling a sub-assembly |
EP3525850B1 (en) * | 2016-10-13 | 2020-12-30 | SHL Medical AG | Sub-assembly for a medicament delivery device |
FR3058895B1 (fr) * | 2016-11-23 | 2024-01-12 | Nemera La Verpilliere | Dispositif d'injection presentant un dispositif de retrait de capuchon de seringue ameliore |
US10661026B2 (en) * | 2016-12-13 | 2020-05-26 | Becton, Dickinson And Company | Safety needle device |
WO2018226994A1 (en) | 2017-06-08 | 2018-12-13 | Becton, Dickinson And Company | Biological fluid separation device |
CH714489A2 (de) | 2017-12-21 | 2019-06-28 | Tecpharma Licensing Ag | Injektionsvorrichtung mit einer Kappe zur Entfernung einer Nadelschutzkappe von einem Produktbehälter und Verfahren zum Vorbereiten einer solchen Injektionsvorrichtung. |
EP3727514A1 (en) | 2017-12-22 | 2020-10-28 | West Pharma Services IL, Ltd. | Injector usable with different dimension cartridges |
GB2570319B (en) | 2018-01-19 | 2021-01-06 | Consort Medical Plc | A medicament delivery device |
CN110681006A (zh) * | 2018-07-06 | 2020-01-14 | 群康生技股份有限公司 | 注射器 |
EP3626291A1 (en) | 2018-09-21 | 2020-03-25 | Regeneron Pharmaceuticals, Inc. | Needle shield grip device |
TWI772669B (zh) * | 2018-09-24 | 2022-08-01 | 瑞士商瑞健醫療股份有限公司 | 針護罩移除器和包括有針護罩移除器的藥物輸送裝置 |
JP7209839B2 (ja) * | 2018-12-12 | 2023-01-20 | エスエイチエル・メディカル・アーゲー | 作動防止キャップアセンブリ |
GB2580142B (en) | 2018-12-21 | 2023-04-12 | Janssen Pharmaceuticals Inc | Accessory for an injection including a pivotable cover |
USD958330S1 (en) | 2018-12-21 | 2022-07-19 | Janssen Pharmaceuticals, Inc. | Injection device accessory |
GB2580141B (en) | 2018-12-21 | 2023-04-12 | Janssen Pharmaceuticals Inc | Accessory for an injection device including a grip for a needle cap |
GB2580133B (en) | 2018-12-21 | 2023-04-12 | Janssen Pharmaceuticals Inc | Accessory including a slot for a flange of an injection device |
AU2020227208B2 (en) | 2019-02-26 | 2022-10-06 | Becton Dickinson France | Auto-injector with needle cover |
CA3127718C (en) * | 2019-02-26 | 2023-10-17 | Becton Dickinson France | Rigid needle shield remover with drop test feature for autoinjector |
KR102660484B1 (ko) * | 2019-02-26 | 2024-04-24 | 벡톤 디킨슨 프랑스 | 캡을 구비한 자동 주사 장치 |
US20230355889A1 (en) * | 2020-03-27 | 2023-11-09 | Jaroslaw Moleda | Needle-based device based on direct wing-based coupling of a needle shield to a barrel thereof and safety mechanism implemented therein |
US20230355892A1 (en) * | 2020-10-14 | 2023-11-09 | Shl Medical Ag | Medicament delivery member guard lock assembly |
USD948715S1 (en) | 2020-11-06 | 2022-04-12 | West Pharmaceutical Services, Inc. | Injection needle shield puller |
CH718182A2 (de) | 2020-12-17 | 2022-06-30 | Ypsomed Ag | Injektionsvorrichtung mit einer Kappe zur Entfernung einer Nadelschutzkappe von einem Produktbehälter und Verfahren zum Vorbereiten einer solchen Vorrichtung. |
CH718181A2 (de) | 2020-12-17 | 2022-06-30 | Ypsomed Ag | Injektionsvorrichtung mit einer Kappe zur Entfernung einer Nadelschutzkappe von einem Produktbehälter und Verfahren zum Vorbereiten einer solchen Vorrichtung. |
AR127250A1 (es) * | 2021-10-06 | 2024-01-03 | Amgen Inc | Herramienta de freno activado por impacto para dispositivo de administración de fármacos |
WO2023222425A1 (en) * | 2022-05-19 | 2023-11-23 | Shl Medical Ag | A subassembly of a medicament delivery device |
WO2024022643A1 (en) * | 2022-07-26 | 2024-02-01 | Shl Medical Ag | Cap for medicament delivery device |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160869A1 (en) | 2002-06-22 | 2010-06-24 | Barry Peter Liversidge | Medical Needle Assemblies |
GB2414400B (en) * | 2004-05-28 | 2009-01-14 | Cilag Ag Int | Injection device |
GB2438590B (en) | 2006-06-01 | 2011-02-09 | Cilag Gmbh Int | Injection device |
GB2438593B (en) * | 2006-06-01 | 2011-03-30 | Cilag Gmbh Int | Injection device (cap removal feature) |
US20080228147A1 (en) * | 2007-03-15 | 2008-09-18 | Bristol-Myers Squibb Company | Injector for use with pre-filled syringes and method of assembly |
GB2451664B (en) | 2007-08-08 | 2012-06-20 | Cilag Gmbh Int | Injection device |
ES2742504T3 (es) * | 2007-09-25 | 2020-02-14 | Becton Dickinson France | Autoinyector con elemento de eliminación de blindaje que comprende medios antimanipulación |
CN101854967B (zh) * | 2007-09-25 | 2013-06-05 | 贝克顿迪金森法国公司 | 具有能由安全护套移动的解除作用装置的自动注射器 |
EP2203204B1 (en) * | 2007-09-25 | 2014-12-31 | Becton Dickinson France | Autoinjector |
GB2461087B (en) | 2008-06-19 | 2012-09-26 | Cilag Gmbh Int | Injection device |
GB0901801D0 (en) * | 2009-02-05 | 2009-03-11 | Medical House Plc The | Improved autoinjector |
DK3421067T3 (da) | 2009-05-29 | 2022-02-28 | Ypsomed Ag | Injektionsindretning, især auto-injektor, med en nålebeskyttelse og/eller overbelastningssikring til en produktbeholder |
EP2364740A1 (en) | 2010-03-09 | 2011-09-14 | Sanofi-Aventis Deutschland GmbH | Arrangement for transferring a translation of a drive means to a plunger |
GB201020472D0 (en) | 2010-12-02 | 2011-01-19 | Oval Medical Technologies Ltd | A drive assembly for an autoinjector |
EP2468340A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto injector with an interlock switch detecting the position of the needle shroud |
GB201021717D0 (en) * | 2010-12-22 | 2011-02-02 | Owen Mumford Ltd | Autoinjectors |
KR101989342B1 (ko) * | 2011-01-24 | 2019-06-14 | 애브비 바이오테크놀로지 리미티드 | 주사기로부터 니들 실드의 제거 및 자동 주사 디바이스들 |
WO2012101629A1 (en) * | 2011-01-24 | 2012-08-02 | Elcam Medical Agricultural Cooperative Association Ltd. | Injector |
WO2012122643A1 (en) * | 2011-03-11 | 2012-09-20 | University Of Saskatchewan | Injection assist device and method |
ES2661932T5 (es) * | 2011-07-05 | 2024-04-23 | Shl Medical Ag | Conjunto de elemento de extracción de vaina de aguja |
AU2012306063B2 (en) | 2011-09-09 | 2017-05-25 | Merck Patent Gmbh | Reloadable auto-injector |
EP2578188A1 (en) * | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
WO2013058697A1 (en) * | 2011-10-17 | 2013-04-25 | Shl Group Ab | Device for removing delivery member shields |
KR101664782B1 (ko) * | 2012-03-14 | 2016-10-24 | 케어베이 유럽 리미티드 | 약물 전달 장치 |
GB201212190D0 (en) * | 2012-07-09 | 2012-08-22 | Oval Medical Technologies Ltd | Injector device with mechanism for preventing accidental activation |
FR2999436B1 (fr) * | 2012-12-14 | 2016-02-05 | Transformation Des Elastomeres A Usages Medicaux Et Ind Soc D | Systeme de protection d'aiguille d'un dispositif d'injection. |
FR3002739B1 (fr) * | 2013-03-01 | 2016-01-08 | Transformation Des Elastomeres A Usages Medicaux Et Ind Soc D | Dispositif de protection d'aiguille. |
EA028936B1 (ru) | 2013-03-08 | 2018-01-31 | Тева Фармасьютикал Индастриз Лимитед | Инъекторное устройство многократного использования для шприца |
US8591463B1 (en) * | 2013-03-08 | 2013-11-26 | Teva Pharmaceutical Industries Ltd. | Re-useable injector device for syringe |
CN105163782A (zh) * | 2013-03-25 | 2015-12-16 | 卡贝欧洲有限公司 | 用于药物输送装置的前帽 |
CN104602741B (zh) * | 2013-03-26 | 2018-10-26 | 泰尔茂株式会社 | 弹性帽以及具备所述弹性帽的注射器用组装体 |
FR3011186B1 (fr) * | 2013-09-30 | 2017-12-08 | Rexam Healthcare La Verpillier | Dispositif de reception pour une seringue d'injection comprenant un capuchon de protection de l'aiguille |
FR3011473B1 (fr) * | 2013-10-08 | 2015-12-18 | Aptar Stelmi Sas | Dispositif de protection pour aiguille de seringue. |
ES2610249T3 (es) * | 2014-01-30 | 2017-04-26 | Tecpharma Licensing Ag | Dispositivo de seguridad de liberación para un autoinyector |
CH707216A2 (de) * | 2014-03-06 | 2014-04-30 | Tecpharma Licensing Ag | Verbesserte automatische Injektionsvorrichtung. |
EP2923716A1 (en) * | 2014-03-28 | 2015-09-30 | Sanofi-Aventis Deutschland GmbH | Cap having a sheath removal mechanism |
-
2014
- 2014-03-28 EP EP14162455.1A patent/EP2923716A1/en not_active Ceased
-
2015
- 2015-03-26 TW TW104109666A patent/TW201603853A/zh unknown
- 2015-03-27 US US15/124,790 patent/US10188802B2/en active Active
- 2015-03-27 JP JP2016558392A patent/JP6616315B2/ja active Active
- 2015-03-27 CN CN201580015085.3A patent/CN106132462B/zh active Active
- 2015-03-27 EP EP20174948.8A patent/EP3714927A1/en active Pending
- 2015-03-27 EP EP15715196.0A patent/EP3122403B1/en active Active
- 2015-03-27 DK DK15715196.0T patent/DK3122403T3/da active
- 2015-03-27 WO PCT/EP2015/056687 patent/WO2015144871A1/en active Application Filing
-
2019
- 2019-01-14 US US16/222,760 patent/US11400233B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10188802B2 (en) | 2019-01-29 |
EP3122403A1 (en) | 2017-02-01 |
EP3122403B1 (en) | 2020-06-24 |
US20170014578A1 (en) | 2017-01-19 |
DK3122403T3 (da) | 2020-09-14 |
CN106132462B (zh) | 2020-01-17 |
TW201603853A (zh) | 2016-02-01 |
JP2017508548A (ja) | 2017-03-30 |
WO2015144871A1 (en) | 2015-10-01 |
US11400233B2 (en) | 2022-08-02 |
US20190117902A1 (en) | 2019-04-25 |
EP2923716A1 (en) | 2015-09-30 |
CN106132462A (zh) | 2016-11-16 |
EP3714927A1 (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6616315B2 (ja) | シース取外し機構 | |
US20200254181A1 (en) | Autoinjector | |
JP6498189B2 (ja) | 自己注射器(Autoinjector) | |
JP6043806B2 (ja) | 自動注射器 | |
JP6475237B2 (ja) | 自動注射器 | |
JP6412121B2 (ja) | 自己注射器(Autoinjector) | |
JP6622694B2 (ja) | 2つの駆動ばねを備えた薬剤送達デバイス | |
JP6212047B2 (ja) | 自動注射器 | |
JP6043805B2 (ja) | 外側プランジャと係合解除してシリンジ・キャリアを後退させる内側プランジャ付きの自動注射器 | |
JP6408571B2 (ja) | 自動注射器 | |
JP6577942B2 (ja) | 注射デバイス | |
JP6412215B2 (ja) | 薬剤送達デバイスおよび薬物送達デバイス用作動機構 | |
JP6165747B2 (ja) | 自動注射器 | |
JP6073462B2 (ja) | カートリッジホルダおよびペン型注射器 | |
JP2016538058A (ja) | 針安全デバイス(needle safety device)および薬物送達デバイス | |
JP6487428B2 (ja) | 自動注射器(Autoinjector) | |
JP2016534790A (ja) | 薬剤送達デバイス | |
JP6326054B2 (ja) | 使用状態インジケータを備える薬剤送達デバイス | |
JP2015501690A (ja) | 安全シリンジ | |
JP2017504422A (ja) | 薬剤送達デバイス | |
JP2018506379A (ja) | 薬剤送達デバイスおよびその組み立て方法 | |
JP2016523671A (ja) | 自動注射器 | |
JP2016529014A (ja) | 薬剤容器用の安全デバイス | |
JP2016540577A (ja) | 針安全デバイスおよび薬物送達デバイス | |
JP2018513753A (ja) | 薬物送達デバイス |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180314 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180314 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190507 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191008 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191107 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6616315 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |